Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.
about
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors from Natural Products: Discovery of Next-Generation Antihyperglycemic AgentsThe role of kidney in glucose homeostasis--SGLT2 inhibitors, a new approach in diabetes treatment.Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetesRandomized trial showing efficacy and safety of twice-daily remogliflozin etabonate for the treatment of type 2 diabetes.Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes.Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes.SGLT-2 Inhibitors: A New Mechanism for Glycemic Control.Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetesSafety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus.Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus.Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus.Sweet & low: new treatment for diabetes that may reduce blood pressure.The kidney as a new target for antidiabetic drugs: SGLT2 inhibitors.Ramping glucosuria for management of type 2 diabetes mellitus: an emerging cynosure.Lowering plasma glucose concentration by inhibiting renal sodium-glucose cotransport.Natural product and natural product derived drugs in clinical trials.Sodium-glucose cotransport inhibitors: mechanisms, metabolic effects and implications for the treatment of diabetic patients with chronic kidney disease.Dapagliflozin: drug profile and its role in individualized treatment.Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus.The potential of SGLT2 inhibitors in phase II clinical development for treating type 2 diabetes.Antidiabetic Effect of Schisandrae Chinensis Fructus Involves Inhibition of the Sodium Glucose Cotransporter.Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview.Remogliflozin Etabonate Improves Fatty Liver Disease in Diet-Induced Obese Male MiceRegional gastrointestinal delivery of remogliflozin etabonate in humans.Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects.
P2860
Q28074843-0B74808C-8C5F-4672-AF96-B93C536023D1Q30663494-06E449E1-2F32-4D4C-B891-FC971ED5FA04Q34301921-53E9316E-DDD6-43E8-B1F7-65DB0C10DCD2Q34438769-7D92A2B9-35A5-4AFA-8A30-59A19F0F4607Q34439528-D78625C2-59D7-4F9E-AFF7-3E553C9D5D2DQ35111555-DA3381FD-FF59-46A5-AC55-6D908827C774Q35906490-247E28AF-8E3A-49E5-B302-49EF8448CF06Q36221586-CD560B0E-E3A8-4E3B-B4FF-F744D0290428Q36929947-9E5F7278-192D-4B36-B038-B0F07E64C79FQ38075117-CD78DFC1-FD04-46A2-9B7C-2DD4FF52495BQ38085691-4729D76B-929C-4298-A543-63E631D018FAQ38101387-B3FF6486-A209-4DA8-8C8B-0E2BC04624E1Q38126109-18C4CCA7-1B68-4187-AE85-4F3E2B44FD66Q38196340-6D65C7F9-0292-445D-9845-911508C0541BQ38201162-DB1F14C3-6350-4B0C-A35A-66858141DAB6Q38247457-7E589240-056F-4A01-9A85-CF4F8D89FD20Q38250445-76849551-81D7-46D6-B7FA-7A35CE529CB9Q38308333-3A14DA1B-5F28-478F-8BEE-4F54F08D3D04Q38569449-490E0BC1-2986-4E02-8DAF-86F8FA091D44Q38908779-A7D98B4A-34ED-4E8D-8526-BD4F5F349212Q38939488-95F642B8-9A13-48A1-B12F-D1B6B9C731EFQ38975736-208CF4D6-4FDA-4640-A2A1-89B232F77A8AQ42107886-39655EA5-5A0D-455A-B81C-D2728123D151Q42674755-3F4447A9-2CBB-49CF-8B05-2CADFA334EF2Q47100805-664D53BF-4144-403A-84B4-7F581D94DD58
P2860
Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients.
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Remogliflozin etabonate, a sel ...... 2 diabetes mellitus patients.
@ast
Remogliflozin etabonate, a sel ...... 2 diabetes mellitus patients.
@en
type
label
Remogliflozin etabonate, a sel ...... 2 diabetes mellitus patients.
@ast
Remogliflozin etabonate, a sel ...... 2 diabetes mellitus patients.
@en
prefLabel
Remogliflozin etabonate, a sel ...... 2 diabetes mellitus patients.
@ast
Remogliflozin etabonate, a sel ...... 2 diabetes mellitus patients.
@en
P2093
P2860
P1476
Remogliflozin etabonate, a sel ...... 2 diabetes mellitus patients.
@en
P2093
E K Hussey
I Mikoshiba
R L Dobbins
R O'Connor-Semmes
P2860
P356
10.1111/J.1463-1326.2011.01462.X
P577
2011-10-30T00:00:00Z